A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma

BMC Cancer

Table 3 Univariate and Multivariate Cox regression analysis of the lncRNA signature and survival in different patient cohorts

Variables	Unfavorable/Favorable	Univariate			Multivariate
Variables	Unfavorable/Favorable	HR	95% CI	P vaule	HR	95% CI	P vaule
Discovery cohort (n = 150)
11-lncRNA risk score	High/Low	2.718	1.923–3.842	<0.001	2.649	1.788–3.923	<0.001
Age		1.055	1.004–1.108	0.035	0.992	0.931–1.057	0.797
Stage	(III + IV)/(I + II)	4.122	1.588–10.7	0.004	1.219	0.392–3.795	0.732
Grade	3/(1 + 2)	4.397	1.258–15.37	0.020	1.609	0.397–6.52	0.506
Histology	Serous/Endometrioid	1.731	0.604–4.962	0.307	0.728	0.217–2.445	0.607
Validation cohort (n = 151)
11-lncRNA risk score	High/Low	6.903	1.521–31.340	0.012	6.158	1.205–31.465	0.029
Age		1.042	0.986–1.101	0.141	1.046	0.975–1.122	0.208
Stage	(III + IV)/(I + II)	7.160	2.196–23.340	0.001	7.153	1.601–31.955	0.010
Grade	3/(1 + 2)	2.632	0.879–7.885	0.084	0.681	0.150–3.083	0.618
Histology	Serous/Endometrioid	4.873	1.627–14.600	0.005	0.691	0.099–4.830	0.709
Entire TCGA cohort (n = 301)
11-lncRNA risk score	High/Low	11.767	3.568–38.810	<0.001	10.793	3.084–37.777	<0.001
Age		1.050	1.012–1.09	0.009	1.064	1.018–1.112	0.006
Stage	(III + IV)/(I + II)	4.835	2.359–9.906	<0.001	3.948	1.759–8.859	0.001
Grade	3/(1 + 2)	3.206	1.433–7.177	0.005	1.263	0.490–3.257	0.628
Histology	Serous/Endometrioid	2.584	1.236–5.402	0.012	0.509	0.209–1.240	0.137

ISSN: 1471-2407